Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 602.

https://doi.org/10.1182/blood-2019-130644

Published: 2019

Journal Articles

Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Jordan Nunnelee, BA, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 4573.

https://doi.org/10.1182/blood-2019-121845

Published: 2019

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

https://doi.org/10.1182/blood-2019-129128

Published: 2019

Journal Articles

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Jordon Jaggers, Heidi D. Klepin, MD, Tanya M. Wildes, MD, Rebecca L. Olin, MD, Andrew S. Artz, MD, Sarah A Wall, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5819.

https://doi.org/10.1182/blood-2019-131504

Published: 2019

Journal Articles

Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 4549.

https://doi.org/10.1182/blood-2019-122626

Published: 2019

Journal Articles

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Michael Ozga, MD, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Patrick Elder, MS, Nita Williams, Naresh Bumma, MD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Rami Kahwash, MD, Ajay Vallakati, MD, Courtney Campbell, MD PhD, Samir Parikh, MD, Salem Almaani, MD, Jason Prosek, MD, Elyse Redder, PT, CLT-LANA, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 1833.

https://doi.org/10.1182/blood-2019-124206

Published: 2019

Journal Articles

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Joseph Maakaron, MD, Qiuhong Zhao, MS, Marcin Puto, PharmD, Quinn Verfurth, Sam Penza, MD, Jonathan E Brammer, MD, Yvonne A. Efebera, MD MPH, Ashley E. Rosko, MD, Ayman Saad, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD

Blood (2019) 134 (Supplement_1): 2024.

https://doi.org/10.1182/blood-2019-126994

Published: 2019

Journal Articles

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Blood (2019) 134 (Supplement_1): 2029.

https://doi.org/10.1182/blood-2019-130307

Published: 2019

Journal Articles

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Robert A Baiocchi, MD PhD, Don M. Benson, Jr., MD PhD, Jonathan E. Brammer, MD, John C. Byrd, MD, Yvonne A. Efebera, MD MPH, Kami J. Maddocks, MD, Kerry A. Rogers, MD, Carolyn Presley, MD, Desiree Jones, Ying Huang, MS, MA, Michelle Naughton, PhD MPH

Blood (2019) 134 (Supplement_1): 4776.

https://doi.org/10.1182/blood-2019-130531

Published: 2019

Journal Articles

Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant

Lucas Fabienne, PhD, Michael Pennell, PhD, Don M. Benson, Jr., MD PhD, Yvonne Efebera, MD, Maria Chaudhry, MD, Jennifer A. Woyach, MD, Xiangnan Guan, Zhang Suohui, Christin E Burd, PhD, Ashley E. Rosko, MD

Blood (2018) 132 (Supplement 1): 3434.

https://doi.org/10.1182/blood-2018-99-119577

Published: 2018

Journal Articles

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Blood (2018) 132 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2018-99-114100

Published: 2018

Journal Articles

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

Ravi Vij, MBBS, Nitya Nathwani, MD, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L Kaufman, MD, Craig C Hofmeister, MDMPH, Tara Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2018) 132 (Supplement 1): 123.

https://doi.org/10.1182/blood-2018-99-109920

Published: 2018

Journal Articles

Exercise Is Medicine: Restoring Function in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Carolyn Presley, MD, ReNea Owens, Desiree Jones, Ying Huang, MA, MS, Michelle Naughton, PhD MPH

Blood (2018) 132 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2018-99-120167

Published: 2018

Journal Articles

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up

Nidhi Sharma, PhD MS, Nita Williams, BS, Ashley E. Rosko, MD, Don M. Benson, Jr., MD PhD, Maria Chaudhry, MD, Craig C Hofmeister, MD MPH, Douglas W. Sborov, MD MS, Yvonne Efebera, MD

Blood (2018) 132 (Supplement 1): 2155.

https://doi.org/10.1182/blood-2018-99-116460

Published: 2018

Journal Articles

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

Taylor Gonzalez, Evan C Catton, Ashley E. Rosko, MD, Yvonne Efebera, MD, Maria Chaudhry, MD, Francesca Cottini, MD, Bethany L Mundy-Bosse, PhD, Tiffany Hughes, BS, PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2018-99-117465

Published: 2018

Journal Articles

B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma

Syed Basir Hussaini, BS, Jacqueline Chu, BA, Nita Williams, BS, Nidhi Sharma, PhD, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 3356.

https://doi.org/10.1182/blood.V130.Suppl_1.3356.3356

Published: 2017

Journal Articles

Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

Hallie Barr, PharmD, Jessica Dempsey, PharmD, BCOP, Allyson Waller, PharmD, Ying Huang, MD, Nita Williams, BS, Nidhi Sharma, PhD, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 1889.

https://doi.org/10.1182/blood.V130.Suppl_1.1889.1889

Published: 2017

Journal Articles

Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis

Jacqueline Chu, BA, Syed Basir Hussaini, BS, Nidhi Sharma, PhD, Nita Williams, BS, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 4645.

https://doi.org/10.1182/blood.V130.Suppl_1.4645.4645

Published: 2017

Journal Articles

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Daniel R Richardson, MD, Ying Huang, MA, MS, Patrick Elder, MS, Joanna Newlin, LISW, Cyndi Kirkendall, LISW, Steven M Devine, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Craig C Hofmeister, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Heather L McGinty, PhD, Sam Penza, MD, Sumithra Vasu, MBBS, Basem M William, MD, Ashley E Rosko, MD

Blood (2016) 128 (22): 1241.

https://doi.org/10.1182/blood.V128.22.1241.1241

Published: 2016

Journal Articles

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3409.

https://doi.org/10.1182/blood.V128.22.3409.3409

Published: 2016

NARROW

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

Exercise Is Medicine: Restoring Function in Older Adults with Hematologic Malignancy

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma

Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only